The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The reverse Warburg Effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts
Open accessAbstract
We and others have previously identified a loss of stromal caveolin-1 (Cav-1) in cancer-associated fibroblasts (CAFs) as a powerful single independent predictor of breast cancer patient tumor recurrence, metastasis, tamoxifen-resistance, and poor clinical outcome. However, it remains unknown how loss of stromal Cav-1 mediates these effects clinically. To mechanistically address this issue, we have now generated a novel human tumor xenograft model. In this two-component system, nude mice are co-injected with i) human breast cancer cells (MDA-MB-231), and ii) stromal fibroblasts (wild-type (WT) versus Cav-1 (-/-) deficient). This allowed us to directly evaluate the effects of a Cav-1 deficiency solely in the tumor stromal compartment. Here, we show that Cav-1-deficient stromal fibroblasts are sufficient to promote both tumor growth and angiogenesis, and to recruit Cav-1 (+) micro-vascular cells. Proteomic analysis of Cav-1-deficient stromal fibroblasts indicates that these cells upregulate the expression of glycolytic enzymes, a hallmark of aerobic glycolysis (the Warburg effect). Thus, Cav-1-deficient stromal fibroblasts may contribute towards tumor growth and angiogenesis, by providing energy-rich metabolites in a paracrine fashion. We have previously termed this new idea the "Reverse Warburg Effect". In direct support of this notion, treatment of this xenograft model with glycolysis inhibitors functionally blocks the positive effects of Cav-1-deficient stromal fibroblasts on breast cancer tumor growth. Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for breast cancer patients that lack stromal Cav-1 expression. We also identify the stromal expression of PKM2 and LDH-B as new candidate biomarkers for the "Reverse Warburg Effect" or "Stromal-Epithelial Metabolic Coupling" in human breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Function of Mitochondrial Stat3 in Cellular Respiration
Wegrzyn, J., Potla, R., Chwae, Y.-J., Sepuri, N. B. V., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009) · Science · doi:10.1126/science.1164551 · Cited by 1,014
Cited by
Wallace, D. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3365 · Cited by 2,404
Targeting lactate metabolism for cancer therapeutics
Doherty, J. R., & Cleveland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69741 · Cited by 1,166
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy
Yang, Y., Karakhanova, S., Hartwig, W., D'Haese, J. G., Philippov, P. P., Werner, J., & Bazhin, A. V. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25349 · Cited by 672
Mechanisms and Implications of Metabolic Heterogeneity in Cancer
Kim, J., & DeBerardinis, R. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.013 · Cited by 606
Lee, S. Y., Jeong, E. K., Ju, M. K., Jeon, H. M., Kim, M. Y., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0577-4 · Cited by 578
Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B., Frank, P. G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U. E., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12731 · Cited by 576
Self-citationErin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Yang, E., Wang, X., Gong, Z., Yu, M., Wu, H., & Zhang, D. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00359-5 · Cited by 494
Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
Li, Z., Sun, C., & Qin, Z. (2021) · Theranostics · doi:10.7150/thno.62378 · Cited by 390
Wilde, L., Roche, M., Domingo-Vidal, M., Tanson, K., Philp, N., Curry, J., & Martinez-Outschoorn, U. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.004 · Cited by 326
Self-citationPavlides, S., Vera, I., Gandara, R., Sneddon, S., Pestell, R. G., Mercier, I., Martinez-Outschoorn, U. E., Whitaker-Menezes, D., Howell, A., Sotgia, F., et al. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4243 · Cited by 289
Self-citationCancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Colwell, N., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., & Park, D. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now258 · Cited by 284
Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms
Sotgia, F., Martinez-Outschoorn, U. E., Howell, A., Pestell, R. G., Pavlides, S., & Lisanti, M. P. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-120856 · Cited by 281
Self-citationJia, D., Park, J., Jung, K., Levine, H., & Kaipparettu, B. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 270
Fu, Y., Liu, S., Yin, S., Niu, W., Xiong, W., Tan, M., Li, G., & Zhou, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18175 · Cited by 263
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
Bluemlein, K., Grüning, N.-M., Feichtinger, R. G., Lehrach, H., Kofler, B., & Ralser, M. (2011) · Oncotarget · doi:10.18632/oncotarget.278 · Cited by 253
Witkiewicz, A. K., Whitaker-Menezes, D., Dasgupta, A., Philp, N. J., Lin, Z., Gandara, R., Sneddon, S., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19530 · Cited by 239
Self-citationLisanti, M. P., Martinez-Outschoorn, U. E., Chiavarina, B., Pavlides, S., Whitaker-Menezes, D., Tsirigos, A., Witkiewicz, A. K., Lin, Z., Balliet, R. M., Howell, A., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13370 · Cited by 199
Self-citationCatabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer
Kennedy, K. M., Scarbrough, P. M., Ribeiro, A., Richardson, R., Yuan, H., Sonveaux, P., Landon, C. D., Chi, J.-T., Pizzo, S., Schroeder, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075154 · Cited by 190
Martinez-Outschoorn, U. E., Pestell, R. G., Howell, A., Tykocinski, M. L., Nagajyothi, F., Machado, F. S., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18487 · Cited by 157
Crawford, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00068 · Cited by 108
Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
Brauer, H. A., Makowski, L., Hoadley, K. A., Casbas-Hernandez, P., Lang, L. J., Romàn-Pèrez, E., D'Arcy, M., Freemerman, A. J., Perou, C. M., & Troester, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2123 · Cited by 96
Metadata
- Authors
- Bonuccelli, G., Whitaker-Menezes, D., Castello-Cros, R., Pavlides, S., Pestell, R. G., Fatatis, A., Witkiewicz, A. K., Vander Heiden, M. G., Migneco, G., Chiavarina, B., Frank, P. G., Capozza, F., Flomenberg, N., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2010-05-15
- Volume
- 9
- Issue
- 10
- Pages
- 1960-1971
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W1965393351
- Cited by
- 220
- References
- 2
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.